References
- Rai K, Gupta S, Cotter S. Experience with Implanon in a north-east London family planning clinic. Eur J Contracept Reprod Health Care 2004; 9: 39–46
- Lakha F, Glasier A F. Continuation rates of Implanon in the UK: Data from an observational study in a clinical setting. Contraception 2006; 74: 287–9
- Agrawal A, Robinson C. An assessment of the first 3 years' use of Implanon in Luton. J Fam Plann Reprod Health Care 2005; 31: 310–2
- Chaovisitsaree S, Piyamongkol W, Pongsatha S, et al. One year study of Implanon on the adverse events and discontinuation. J Med Assoc Thai 2005; 88: 314–7
- Bitzer J, Tschudin S, Alder J. Acceptability and side-effects of Implanon in Switzerland: A retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care 2004; 9: 278–84
- Implanon® (etonogestrel implant). Full Prescribing Information. NV Organon, (part of Schering-Plough), OssThe Netherlands 2005
- Makarainen L, van Beek A, Tuomivaara L, et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 1998; 69: 714–21
- Davies G C, Feng L X, Newton J R, et al. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception 1993; 47: 251–61
- Harrison-Woolrych M, Hill R. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Contraception 2005; 71: 306–8
- Wenzl R, Van Beek A, Schnabel P, et al. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception 1998; 58: 283–8
- McCann M F, Potter L S, IV. Efficacy and pregnancy outcomes. Progestin-only oral contraception: a comprehensive review. Contraception, M F McCann, L S Potter, 1994; 50(Suppl.1): S34–S53